Baseline population characteristics (n = 110). Data are mean ± SD unless otherwise indicated.
| Characteristic | |
|---|---|
| Gender and ethnicity, n (%) | |
| Men/women | 54 (49)/56 (51) |
| White/other | 103 (94)/7 (6) |
| Age, yrs | 48.4 ± 10.9 |
| Age < 65 yrs | 105 (95) |
| Prior treatments, % | |
| DMARD | 89 |
| NSAID | 83 |
| Steroids | 46 |
| Analgesics | 26 |
| Phototherapy | 8 |
| Tar products | 4 |
| Biologics | 3 |
| Emollients | 1 |
| Retinoids | 1 |
| Duration of psoriasis, yrs | 16.2 ± 12.7 |
| Duration of PsA, yrs | 8.9 ± 8.4 |
| Patients with fair, poor, or very poor disease control (physician global assessment) (%) | 109/110 (99) |
| PASI score | 4.8 ± 7.8 |
| HAQ-DI | 1.5 ± 0.6 |
| Joint pain/tenderness score | 30.3 ± 20.2 |
| Joint swelling score | 18.9 ± 13.9 |
HAQ-DI: Health Assessment Questionnaire Disability Index; PASI: Psoriasis Area and Severity Index; PsA: psoriatic arthritis; NSAID: nonsteroidal antiinflammatory drugs; DMARD: disease-modifying antirheumatic drugs.